Entrada Therapeutics Inc · Q1 2025 earnings

Briefing

Entrada Therapeutics reported a decrease in collaboration revenue and a net loss for Q1 2025, driven by a significant catch-up adjustment in the prior year, while continuing to advance its clinical programs.

Entrada Therapeutics reported a net loss of $17.349 million for the three months ended March 31, 2025, a significant decrease from a net income of $23.496 million in the same period last year. This was primarily due to a decrease in collaboration revenue, which was $20.558 million in Q1 2025 compared to $59.120 million in Q1 2024, largely influenced by a $38.7 million cumulative catch-up adjustment in the prior year. Operating expenses increased to $42.348 million from $38.007 million.

• Collaboration revenue significantly decreased to $20.558 million in Q1 2025 from $59.120 million in Q1 2024, primarily due to a large catch-up adjustment in the prior year.
• The company reported a net loss of $17.349 million in Q1 2025, a notable shift from a net income of $23.496 million in Q1 2024.
• Operating expenses increased by $4.341 million, driven by higher research and development costs and general and administrative expenses.
• Cash, cash equivalents, and marketable securities totaled $382.5 million as of March 31, 2025, which is expected to fund operations into Q2 2027.

Headline financials

Revenue & EPS history

Entrada Therapeutics expects to incur significant expenses and operating losses for the foreseeable future as it advances its preclinical and clinical development programs. The company anticipates increased costs associated with operating as a public company and expanding its portfolio. It believes its current cash, cash equivalents, and marketable securities will be sufficient to fund operations into Q2 2027, but additional financing may be required thereafter.